pVITRO1-neo-mcs

A multigenic plasmid for high levels of expression

Catalog code: pvitro1-nmcs

https://www.invivogen.com/pvitro1-mcs

For research use only

Version 19L17-MM

PRODUCT INFORMATION

Contents

- 20 µg of pVITRO1-neo-mcs provided as lyophilized DNA

Storage and stability

- Products are shipped at room temperature.
- Lyophilized DNA should be resuspended upon receipt and stored at -20°C. Lyophilized DNA is stable for 3 months at -20°C. Resuspended DNA is stable for at least one year at -20°C.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pVITRO is a family of plasmids developed mainly for *in vitro* studies. They allow the ubiquitous and constitutive co-expression of two genes of interest. pVITRO plasmids can be stably transfected in mammalian cells and the genes of interest are expressed at high levels. Each pVITRO plasmid is available with either two multiple cloning sites or two reporter genes.

pVITRO1-neo-mcs plasmid is selectable with kanamycin in *E. coli* and G418 in mammalian cells. It contains two multiple cloning sites (MCS) for the convenient cloning of two cDNAs.

PLASMID FEATURES

• **rEF1 and mEF1 prom:** pVITRO1-neo-mcs plasmid carries two elongation factor 1 alpha (EF-1α) promoters, from rat and mouse origins. Similarly to their human counterpart[1], both promoters display a strong activity that yield similar levels of expression. EF-1α promoters are expressed at high levels in all cell cycles and lower levels during G0 phase. EF-1α promoters are also non-tissue specific; they are highly expressed in all cell types.

• **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range[2]. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells.

• **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer[3].

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*[4]

• **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression[5].

• **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

• **Neo:** The *neo* gene from Tn5 confers resistance to Kanamycin in *E. coli* and G418 in mammalian cells. In bacteria, *neo* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *neo* is transcribed from the rat EF-1α promoter as a polycistronic mRNA and translated via the FMDV IRES.

• **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

• **MCS1 and MCS2:** To facilitate cloning each multiple cloning site contains several restriction sites that are compatible with many other enzymes.

MCS1 contains ***Bsp* EI, *Bst* 1107I, *Bam* HI, *Bsi* WI and *Avr* II.**

- *Bsp* EI is compatible with *Age* I and *Sgr* AI.
- *Bst* 1107I (blunt-end restriction enzyme)
- *Bam* HI is compatible with *Bgl* II, *Bst* YI and *Bcl* I.
- *Bsi* WI is compatible with *Acc* 65I, *Ban* I *and Bsr* GI.
- *Avr* II is compatible with *Xba* I, *Spe* I and *Nhe* I.

MCS2 contains ***Age* I, *Eco* RV, *Bgl* II, *Bsr* GI, *and Nhe* I.**

- *Age* I is compatible with *Bsp* EI and *Sgr* AI.
- *Eco* RV (blunt-end restriction enzyme)
- *Bgl* II is compatible with *Bam* HI, *Bst* YI and *Bcl* I.
- *Bsr* GI is compatible with *Acc* 65I, *Ban* I *and Bsi* WI.
- *Nhe* I is compatible with *Xba* I, *Spe* I and *Avr* II.

1. Kim DW. *et al.*, 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91(2):217-23. **2. Moreau P. *et al.*, 1981.** The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res. 9(22):6047-68. **3. Boshart M. *et al.*, 1985.** A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 141(2):521-30. **4. Carswell S. & Alwine J.C. 1989.** Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell Biol. 10: 4248-4258. **5. Ramesh N *et al.*, 1996.** High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res. 24(14):2697-700.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Bacterial antibiotic selection

Kanamycin (not provided) is normally used for *E. coli* at a final concentration of 50 µg/ml in liquid or solid media.

Mammalian antibiotic selection

G418 is normally used at a concentration of 400 µg/ml. However, the optimal concentration needs to be determined for your cells.

RELATED PRODUCTS

Product	Description	Cat. Code
ChemiComp GT116 cells	Competent *E. coli* cells	gt116-11
G418	Selection antibiotic	ant-gn-1

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com


pVITRO1-neo-mcs
(6295 bp)
HpaI (6111)
PvuII (66)
EcoRI (5709)
BstBI (5689)
RsrII (5523)
Tth111I (5123)
PvuII (5112)
FspI (5108)
AseI (4820)
HindIII (4735)
XbaI (4396)
AvrII (4331)
BsiWI (4325)
BamHI (4319)
Bst1107I (4313)
BspEI (4307)
XmnI (4180)
SmaI (3923)
HindIII (3665)
SmaI (1180)
AgeI (1561)
EcoRV (1567)
BglII (1575)
BsrGI (1581)
NheI (1587)
HpaI (1725)
PacI (1827)
PacI (2567)
EF1 pAn
SV40 enh
mEF1 prom
neo
EM7
FMDV IRES
MCS1
MCS2
SV40 pAn
pMB1 Ori
rEF1 prom
CMV enh
190


PvuII (66)
SmaI (1180)
EcoRV (1567) BsrGI (1581)
AgeI (1561) BglII (1575) NheI (1587)
HpaI (1725)
PacI (1827)
PacI (2567)


3401 ccgggctgatatgcgagtgtcgtccgcagggtttagctgtgagcattcccacttcgagtggcgggcggtgcgggggtgagagtgcgaggcctagcggcaa
3501 ccccgtagcctcgcctcgtgtccggcttgaggcctagcgtggtgtccgccgccgcgtgccactccggccgcactatgcgtttttgtccttgctgccctc
HindIII (3665)
3601 gattgccttccagcagcatgggctaacaaagggagggtgtggggctcactcttaaggagcccatgaagcttacgttggataggaatggaagggcaggagg
3701 ggcgactggggcccgcccgccttcggagcacatgtccgacgccacctggatggggcgaggcctgtggctttccgaagcaatcgggcgtgagtttagccta
3801 cctgggccatgtggccctagcactgggcacggtctggcctggcggtgccgcgttcccttgcctcccaacaagggtgaggccgtcccgcccggcaccagtt
SmaI (3923)
3901 gcttgcgcggaaagatggccgctcccggggccctgttgcaaggagctcaaaatggaggacgcggcagcccggtggagcgggcgggtgagtcacccacaca
4001 aaggaagagggccttgcccctcgccggccgctgcttcctgtgaccccgtggtctatcggccgcatagtcacctcgggcttctcttgagcaccgctcgtcg
XmnI (4180)
4101 cggcgggggggaggggatctaatggcgttggagtttgttcacatttggtgggtggagactagtcaggccagcctggcgctggaagtcattcttggaatttg
4201 ccccttgagtttggagcgaggctaattctcaagcctcttagcggttcaaaggtattttctaaacccgtttccagGTGTTGTGAAAGCCACCGCTAATTC
BsiWI (4325)
Bst1107I (4313)
BspEI (4307) BamHI (4319) AvrII (4331)
XbaI (439
4301 AAAGCAATCCGGAGTATACGGATCCCGTACGCCTAGGAGCAGGTTTCCCCAATGACACAAAACGTGCAACTTGAAACTCCGCCTGGTCTTTCCAGGTCTA
4401 GAGGGGTAACACTTTGTACTGCGTTTGGCTCCACGCTCGATCCACTGGCGAGTGTTAGTAACAGCACTGTTGCTTCGTAGCGGAGCATGACGGCCGTGGG
4501 AACTCCTCCTTGGTAACAAGGACCCACGGGGCCAAAAGCCACGCCCACACGGGCCCGTCATGTGTGCAACCCCAGCACGGCGACTTTACTGCGAAACCCA
4601 CTTTAAAGTGACATTGAAACTGGTACCCACACACTGGTGACAGGCTAAGGATGCCCTTCAGGTACCCCGAGGTAACACGCGACACTCGGGATCTGAGAAG
HindIII (4735)
4701 GGGACTGGGGCTTCTATAAAAGCGCTCGGTTTAAAAAGCTTCTATGCCTGAATAGGTGACCGGAGGTCGGCACCTTTCCTTTGCAATTACTGACCCTATG
AseI (4820)
4801 AATACACTGACTGTTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAGGAGGGCCACCATGATTGAACAAGATGGATT
4901 GCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCA
5001 GCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGG
PvuII (5112)
FspI (5108)
Tth111I (5123)
5101 GCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCT
5201 TGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGC
5301 ATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGC
5401 TCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACACATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCAT
RsrII (5523)
5501 CGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTC
BstBI (5689)
5601 CTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGAC
EcoRI (5709)
5701 CGACCAAGCGAATTCGCTAGGATTATCCCTAATACCTGCCACCCCACTCTTAATCAGTGGTGGAAGAACGGTCTCAGAACTGTTTGTTTCAATTGGCCAT
5801 TTAAGTTTAGTAGTAAAAGACTGGTTAATGATAACAATGCATCGTAAAACCTTCAGAAGGAAAGGAGAATGTTTTGTGGACCACTTTGGTTTTCTTTTTT
5901 GCGTGTGGCAGTTTTAAGTTATTAGTTTTTAAAATCAGTACTTTTTAATGGAAACAACTTGACCAAAAATTTGTCACAGAATTTTGAGACCCATTAAAAA
6001 AGTTAAATGAGAAACCTGTGTGTTCCTTTGGTCAACACCGAGACATTTAGGTGAAAGACATCTAATTCTGGTTTTACGAATCTGGAAACTTCTTGAAAAT
HpaI (6111)
6101 GTAATTCTTGAGTTAACACTTCTGGGTGGAGAATAGGGTTGTTTTCCCCCCACATAATTGGAAGGGGAAGGAATATCATTTAAAGCTATGGGAGGGTTGC
6201 TTTGATTACAACACTGGAGAGAAATGCAGCATGTTGCTGATTGCCTGTCACTAAAACAGGCCAAAAACTGAGTCCTTGGGTTGCATAGAAAGCTG